Pre-pandemic, the question I would most often get was, “How do I know whom to trust when it comes to health and science information?” Over three years after a new virus began sweeping the globe, the question I hear again and again is, “Why is it that my husband/sister/aunt/father believes in all this conspiratorial nonsense?” As it turns out, the two questions are related (more on that later),…
As treatments for individuals with inherited bleeding disorders improve, life expectancy increases and is approaching that of the normal population. Concomitant with this we are…
Registries are excellent sources of data to address questions that are typically not evaluated in randomized clinical trials, including natural history, disease prevalence, treatment approaches…
Abstract. The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not on
A video from Drew Provan (as part of XIV Eurasian Hematology-Oncology Congress – EHOC 2023), posted on Feb 14, 2024.
Age-dependent effects on plasma VWF levels in type 1 VWD define distinct subgroups with important differences in underlying pathogenesis.Low VWF does not c
Subcutaneous emicizumab administered from birth has the potential to reduce the risk of ICH and joint bleeds before damage occurs.Primary analysis of the H
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
A video from Theodore Warkentin (as part of Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024), posted on Mar 19, 2024.
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries.
